Madrigal is a biopharmaceutical company dedicated to developing innovative therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease that can lead to serious health complications. The company is committed to combating MASH through its flagship medication, Rezdiffra (resmetirom), which is the first and only FDA and European Commission-approved treatment for MASH with moderate to advanced fibrosis. Madrigal fosters a dynamic and inclusive workplace culture that emphasizes scientific excellence, operational rigor, and collaboration among its team members. The company is focused on building a strong workforce strategy to support its growth and ensure the right talent is in place to drive its mission forward.